Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia

References

• Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–3825.
   PubMed Web of Science ®Google Scholar
• Vivona D, Lima LT, Rodrigues AC, et al. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett. 2014;7:1313–1319.
   PubMed Web of Science ®Google Scholar
• Bain BJ. An overview of translocation-related oncogenesis in the chronic myeloid leukaemias. Acta Haematol. 2002;107:57–63.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y. Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy. Jpn J Clin Oncol. 2011;41:157–164.
   PubMed Web of Science ®Google Scholar
• Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet. 2013;58:346–352.
   PubMed Web of Science ®Google Scholar
• Ravegnini G, Angelini S. Managment of gastrointestinal stromal tumors: present and future direction. In: Ahmed AA, editor. Gastrointestinal stromal tumors in adults and children. New York (NY): Nova Biomedical; 2015. p. 135–147.
   Google Scholar
• Angelini S, Ravegnini G, Fletcher JA, et al. Clinical relevance of pharmacogenetics in GIST treatment in the era of personalized therapy. Pharmacogenomics. 2013;14:941–956.
   PubMed Web of Science ®Google Scholar
• Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004;44:158–162.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–894.
   PubMed Web of Science ®Google Scholar
• Polillo M, Galimberti S, Barate C, et al. Pharmacogenetics of BCR/ABL inhibitors in chronic myeloid leukemia. Int J Mol Sci. 2015;16:22811–22829.
   PubMed Web of Science ®Google Scholar
• Ravegnini G, Nannini M, Sammarini G, et al. Personalized medicine in gastrointestinal stromal tumor (GIST): clinical implications of the somatic and germline DNA analysis. Int J Mol Sci. 2015;16:15592–15608.
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–878.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349.
   PubMed Web of Science ®Google Scholar
• Angelini S, Pantaleo MA, Ravegnini G, et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2013;68:1–6.
   PubMed Web of Science ®Google Scholar
• Koo DH, Ryu MH, Ryoo BY, et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2015;75:173–182.
   PubMed Web of Science ®Google Scholar
• Brahmi M, Alberti L, Dufresne A, et al. KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome. BMC Cancer. 2015;15:780.
   PubMed Web of Science ®Google Scholar
• Liu JJ, Ward RL. Folate and one-carbon metabolism and its impact on aberrant DNA methylation in cancer. Adv Genet. 2010;71:79–121.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Sawaki A, Ito S, et al. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut. 2012;61:392–401.
   PubMed Web of Science ®Google Scholar
• Angelini S, Ravegnini G, Nannini M, et al. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Eur J Hum Genet. 2015;23:817–823.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Bylina E, Klimczak A, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure – one institution study. BMC Cancer. 2012;12:107.
   PubMed Web of Science ®Google Scholar
• Bennour A, Saad A, Sennana H. Chronic myeloid leukemia: relevance of cytogenetic and molecular assays. Crit Rev Oncol Hematol. 2016;97:263–274.
   PubMed Web of Science ®Google Scholar
• Maino E, Sancetta R, Viero P, et al. Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther. 2014;14:723–740.
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007;44:S4–S14.
   PubMed Web of Science ®Google Scholar
• Cea M, Cagnetta A, Nencioni A, et al. New insights into biology of chronic myeloid leukemia: implications in therapy. Curr Cancer Drug Targets. 2013;13:711–723.
   PubMed Web of Science ®Google Scholar
• Mu C, Wu X, Ma H, et al. Effective concentration of a multi-kinase inhibitor within bone marrow correlates with in vitro cell killing in therapy-resistant chronic myeloid leukemia. Mol Cancer Ther. 2016. Epub ahead of print.
   Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 2011;117:897–906.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15:4750–4758.
   PubMed Web of Science ®Google Scholar
• Sailaja K, Rao DN, Rao DR, et al. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev. 2010;11:781–784.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Scott SA, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010;55:731–737.
   PubMed Web of Science ®Google Scholar
• Seong SJ, Lim M, Sohn SK, et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol. 2013;24:756–760.
   PubMed Web of Science ®Google Scholar
• Angelini S, Soverini S, Ravegnini G, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013;98:193–200.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112:2024–2027.
   PubMed Web of Science ®Google Scholar
• Deenik W, van der Holt B, Janssen JJ, et al. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood. 2010;116:6144–6145.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Claude P, Guilhot F, et al. Response - Is there really a relationship between multidrug resistance gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood. 2010;116:6145–6146.
   Web of Science ®Google Scholar
• Bazeos A, Marin D, Reid AG, et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia. 2010;24:1243–1245.
   PubMed Web of Science ®Google Scholar
• Ni LN, Li JY, Miao KR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011;28:265–269.
   PubMed Web of Science ®Google Scholar
• Maffioli M, Camos M, Gaya A, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res. 2011;35:1014–1019.
   PubMed Web of Science ®Google Scholar
• Vivona D, Bueno CT, Lima LT, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 2012;48:132–136.
   PubMed Web of Science ®Google Scholar
• Elghannam DM, Ibrahim L, Ebrahim MA, et al. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology. 2014;19:123–128.
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Wang L, Jorgensen AL, et al. The hOCT1 SNP M42del and M408 V alter imatinib uptake and M420del modifies clinical outcome in imatnib-treated chronic myeloid leukemia. Blood. 2013;121:628–637.
   PubMed Web of Science ®Google Scholar
• Ali MAM, Elsalakawi WA. ABCBI haplotypes but not individuals SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Med Oncol. 2014;31:279.
   PubMed Web of Science ®Google Scholar
• Au A, Baba AA, Goh AS, et al. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother. 2014;68:343–349.
   PubMed Web of Science ®Google Scholar
• Vine J, Choen SB, Ruchlemer R, et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014;55:2525–2531.
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Polillo M, Capecchi M, et al. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J. 2014;14:328–335.
   PubMed Web of Science ®Google Scholar
• de Lima LT, Bueno CT, Vivona D, et al. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology. 2015;20:137–142.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368–2373.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169–174.
   PubMed Web of Science ®Google Scholar
• Zu B, Li Y, Wang X, et al. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2014;15:667–677.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Wu H, Yu Q, et al. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 2015;15:127–134.
   PubMed Web of Science ®Google Scholar
• Weiwei C. hOCT1, ABCB1 gene expression and ABCB1 single nucleotide polymorphisms are correlated with the efficacy of imatinib mesylate treatment in chronic myelocytic leukemia [Thesis]. Guangzhou: Southern Medical University; 2012.
   Google Scholar
• Gromicho M, Magalhaes M, Torres F, et al. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep. 2013;29:741–750.
   PubMed Web of Science ®Google Scholar
• Eskzan A, Tatonyan S. Multidrug resistance gene (MDR1) C3435T polymorphism and imatinib response in patients with chronic myeloid leukemia. Blood. 2011;118:21.
   Web of Science ®Google Scholar
• Anthony A, Ankathil R, Goh AS, et al. Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylate in chronic myeloid leukemia patients. Int J Environ Sci Dev. 2012;3:274–278.
   Google Scholar
• Chen WW, Meng FY, Zhong JS, et al. Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia. Zhonghua Yi Xue Za Zhi. 2012;92:1405–1408.
   PubMedGoogle Scholar
• Morisaki K, Robey RW, Ozvegy-Laczka C, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol. 2005;56:161–172.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia. 2010;24:1962–1965.
   PubMed Web of Science ®Google Scholar
• Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17:e81–e86.
   PubMed Web of Science ®Google Scholar
• Nannini M, Ravegnini G, Angelini S, et al. MicroRNAs profiling in gastrointestinal tumors: implication as diagnostic and prognostic markers. Epigenomics. 2015;7:1033–1049.
   PubMed Web of Science ®Google Scholar
• Jurkovicova D, Lukackova R, Magyerkova M, et al. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma. 2015;62:949–958.
   PubMed Web of Science ®Google Scholar